Published in Biomaterials on October 01, 2009
Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano (2010) 2.36
Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small (2010) 2.10
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials (2012) 1.59
Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) (2012) 1.54
Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano (2013) 1.39
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (2011) 1.33
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release (2014) 1.32
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) (2010) 1.28
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine (2011) 1.26
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev (2012) 1.18
P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) (2012) 1.14
Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol (2010) 1.11
Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J Control Release (2013) 1.08
Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One (2012) 1.06
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today (2012) 1.05
Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol (2014) 1.05
Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther (2014) 0.97
Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomedicine (2013) 0.97
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials (2015) 0.92
PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine (2012) 0.90
Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance. Mol Pharm (2014) 0.89
Positron emission tomography image-guided drug delivery: current status and future perspectives. Mol Pharm (2014) 0.88
Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. Int J Nanomedicine (2014) 0.87
Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges. Theranostics (2014) 0.86
Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter (2013) 0.86
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer (2012) 0.85
Materials innovation for co-delivery of diverse therapeutic cargos. RSC Adv (2013) 0.84
Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors. Gene Ther (2014) 0.83
Encapsulation in nanoparticles improves anti-cancer efficacy of carboplatin. AAPS PharmSciTech (2014) 0.82
The delivery of therapeutic oligonucleotides. Nucleic Acids Res (2016) 0.82
Recent development of silica nanoparticles as delivery vectors for cancer imaging and therapy. Nanomedicine (2013) 0.81
Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomedicine (2015) 0.81
Drug resistance in lung cancer. Lung Cancer (Auckl) (2010) 0.80
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol (2013) 0.80
An optimized triple modality reporter for quantitative in vivo tumor imaging and therapy evaluation. PLoS One (2014) 0.79
Preparation and characterization of nanoparticles based on histidine-hyaluronic acid conjugates as doxorubicin carriers. J Mater Sci Mater Med (2012) 0.78
Efficient production of retroviruses using PLGA/bPEI-DNA nanoparticles and application for reprogramming somatic cells. PLoS One (2013) 0.77
Nanotechnology for delivery of peptide nucleic acids (PNAs). J Control Release (2016) 0.77
Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Med Sci (2015) 0.77
Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance. Iran J Basic Med Sci (2016) 0.76
NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer? J Nanobiotechnology (2016) 0.76
Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index. Mol Pharm (2015) 0.75
Smart Mesoporous Nanomaterials for Antitumor Therapy. Nanomaterials (Basel) (2015) 0.75
Modeling nasopharyngeal carcinoma in three dimensions. Oncol Lett (2017) 0.75
Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer-The Case for Combined Delivery? Genes (Basel) (2017) 0.75
Tackling breast cancer chemoresistance with nano-formulated siRNA. Gene Ther (2016) 0.75
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. Front Mol Biosci (2017) 0.75
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 7.08
Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov (2003) 6.66
Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci (2000) 2.81
ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia (2009) 2.43
Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm (2008) 2.07
Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res (2009) 1.81
Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release (2007) 1.79
Super pH-sensitive multifunctional polymeric micelle. Nano Lett (2005) 1.75
Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol (2009) 1.53
Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials (2007) 1.49
Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm (2008) 1.39
Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem (2004) 1.38
Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials (2000) 1.38
Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer (1996) 1.33
Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol (2008) 1.25
Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release (2009) 1.24
Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm (2004) 1.23
Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm (2006) 1.18
Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials (2008) 1.18
Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol Res (2003) 1.16
Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol (2005) 1.14
Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target (2008) 1.13
PLGA-based drug delivery systems: importance of the type of drug and device geometry. Int J Pharm (2007) 1.13
Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv Drug Deliv Rev (2009) 1.12
Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J Control Release (2007) 1.11
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci (2008) 1.10
In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res (2005) 1.10
Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol (2007) 1.10
Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer (1997) 1.08
A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol (2007) 1.08
Recent advances in the development of P-gp inhibitors. Anticancer Agents Med Chem (2009) 1.06
Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm (2007) 1.06
Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther (2005) 1.05
Synthesis and characterisation of a degradable poly(lactic acid)-poly(ethylene glycol) copolymer with biotinylated end groups. Biomacromolecules (2001) 1.05
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol (1998) 1.04
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res (2000) 1.01
Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel (2009) 1.01
Macromolecule release from monodisperse PLG microspheres: control of release rates and investigation of release mechanism. J Pharm Sci (2007) 0.99
Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator. J Pharmacol Exp Ther (2002) 0.97
Acute and chronic in vivo therapeutic resistance. Biochem Pharmacol (2009) 0.95
In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med (2009) 0.91
Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J (2009) 0.88
Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther (2004) 0.88
Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer (2009) 0.87
Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. J Drug Target (2006) 0.87
What Does Multidrug Resistance (MDR) Expression Mean in the Clinic? Oncologist (1996) 0.86
Promising novel cytotoxic agents and combinations in metastatic prostate cancer. Cancer J (2008) 0.85
Novel anti-tubulin cytotoxic agents for breast cancer. Expert Rev Anticancer Ther (2009) 0.85
Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression. Drug Metab Dispos (2005) 0.85
Immunotherapy in a spontaneously developed murine mammary carcinoma with syngeneic monoclonal antibody. Cancer Immunol Immunother (1987) 0.83
Targeting P-glycoprotein for effective oral anti-cancer chemotherapeutics. Curr Cancer Drug Targets (2008) 0.81
Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol Oncol (2005) 0.81
Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature (2007) 5.54
Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release (2002) 2.52
Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood (2009) 2.15
Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm (2002) 2.06
Effects of legal BAC limits on fatal crash involvement: analyses of 28 states from 1976 through 2002. J Safety Res (2007) 1.70
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm (2008) 1.39
General deterrence effects of U.S. statutory DUI fine and jail penalties: long-term follow-up in 32 states. Accid Anal Prev (2007) 1.38
Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. Cancer Res (2010) 1.32
Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release (2009) 1.24
Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery. J Nanosci Nanotechnol (2006) 1.21
Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm (2006) 1.18
Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials (2008) 1.18
Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm (2007) 1.06
Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release (2009) 1.02
Access to quality: evaluation of the allocation of deceased donor kidneys for transplantation. J Am Soc Nephrol (2005) 0.98
Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Eur J Pharm Biopharm (2008) 0.97
Surfactant-polymer nanoparticles enhance the effectiveness of anticancer photodynamic therapy. Mol Pharm (2008) 0.97
Highly loaded, sustained-release microparticles of curcumin for chemoprevention. J Pharm Sci (2011) 0.94
Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials (2013) 0.93
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol Pharm (2012) 0.92
CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release (2013) 0.89
Identification of a novel monoclonal antibody recognizing CD133. J Immunol Methods (2010) 0.89
Polymer-surfactant nanoparticles for sustained release of water-soluble drugs. J Pharm Sci (2007) 0.87
Flash nanoprecipitation: particle structure and stability. Mol Pharm (2013) 0.87
Effective elimination of cancer stem cells by magnetic hyperthermia. Mol Pharm (2013) 0.86
Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules. Pharm Res (2007) 0.85
Polymer nanoparticles: Weighing up gene delivery. Nat Nanotechnol (2013) 0.84
Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res (2011) 0.84
Epithelial proinflammatory response and curcumin-mediated protection from staphylococcal toxic shock syndrome toxin-1. PLoS One (2012) 0.83
Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice. Carcinogenesis (2009) 0.83
The relationship between diabetes and infectious hospitalizations in renal transplant recipients. Diabetes Care (2006) 0.83
Silicate esters of paclitaxel and docetaxel: synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, and prodrug potential. J Med Chem (2014) 0.83
In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. J Med Chem (2014) 0.82
Immunotoxin targeting CD133(+) breast carcinoma cells. Drug Deliv Transl Res (2013) 0.81
Cytosine methylation effects on the repair of O6-methylguanines within CG dinucleotides. J Biol Chem (2009) 0.81
Identification and characterization of a novel scFv recognizing human and mouse CD133. Drug Deliv Transl Res (2013) 0.81
Interfacial activity assisted surface functionalization: a novel approach to incorporate maleimide functional groups and cRGD peptide on polymeric nanoparticles for targeted drug delivery. Mol Pharm (2010) 0.81
Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials (2011) 0.80
Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants. Pharm Res (2007) 0.79
Enhanced photodynamic therapy and effective elimination of cancer stem cells using surfactant-polymer nanoparticles. Mol Pharm (2014) 0.79
Quality of life appears similar between survivors of indolent and aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2011) 0.79
Q-switched waveguide laser based on two-dimensional semiconducting materials: tungsten disulfide and black phosphorous. Opt Express (2016) 0.78
A review of select recent patents on novel nanocarriers. Recent Pat Drug Deliv Formul (2009) 0.78
Preparation of siRNA-encapsulated PLGA nanoparticles for sustained release of siRNA and evaluation of encapsulation efficiency. Methods Mol Biol (2012) 0.78
A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine. J Pharm Sci (2015) 0.77
Assessing the benefits of targeted drug delivery by nanocarriers: A partico/pharmacokinetic framework. IEEE Trans Biomed Eng (2016) 0.75
Image-guided drug delivery in lung cancer. Drug Deliv Transl Res (2012) 0.75